Wellington Management Group LLP raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 14.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,243,599 shares of the biopharmaceutical company's stock after buying an additional 1,167,659 shares during the period. Wellington Management Group LLP owned approximately 13.93% of Celldex Therapeutics worth $314,190,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently modified their holdings of the company. KBC Group NV boosted its holdings in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Celldex Therapeutics in the 2nd quarter worth approximately $76,000. Los Angeles Capital Management LLC grew its position in Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 638 shares in the last quarter. Quest Partners LLC raised its stake in Celldex Therapeutics by 1,364.9% during the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 6,879 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 1,504 shares in the last quarter.
Insider Transactions at Celldex Therapeutics
In other news, CEO Anthony S. Marucci bought 11,500 shares of Celldex Therapeutics stock in a transaction dated Monday, November 11th. The stock was purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. The trade was a 39.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.80% of the company's stock.
Celldex Therapeutics Price Performance
CLDX traded up $0.71 during midday trading on Friday, hitting $26.77. 1,457,491 shares of the company's stock traded hands, compared to its average volume of 969,469. The stock's fifty day simple moving average is $27.80 and its 200-day simple moving average is $34.00. The company has a market cap of $1.78 billion, a PE ratio of -10.42 and a beta of 1.57. Celldex Therapeutics, Inc. has a one year low of $22.93 and a one year high of $53.18.
Analyst Ratings Changes
A number of research analysts have recently weighed in on CLDX shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research note on Monday, September 30th. They set a "neutral" rating and a $45.00 target price on the stock. Citigroup began coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $70.00 price target for the company. Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a report on Friday, September 27th. Finally, Wells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $62.25.
Check Out Our Latest Research Report on Celldex Therapeutics
About Celldex Therapeutics
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Stories
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
